1[1]Brown G,Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med,1990,323:1289～1298.
2[2]Holmes I. An analysis of randomized trials evaluating the effects of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation,1996,82:1916～1924.
3[3]The lipid Research Clinics Program: The Lipid Research Lipid Clinics Program Cor onary Primary Prevention Trial results,II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowing. J Am Assoc, 1998,251:365～374.
4[4]Frick MH, Elo O, Hanpa.K, et al.Helsinki Heart Study:Primary prevention trial with gemfibrozil in middle-age men with dyslipidemia. N Engl J Med,1997,20:1237～1245.
5[5]Manninen V, Huttunen JK, Heinonen OP, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc,1999,260:641～651.
6[6]Casterlli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease: The Cooperative lipoprotein phenol-typing study. Circulation,1997,55:767～772.
7[7]Casterlli WP. The triglycoride issue: A view from Framingham. Am Heart J,1996,112:432～437.
8[8]Austin MA. Plasma triglyceride and coronary and coronary heart disease. Arterioscleros Thrombus,1997,11:214.
